viewAgile Therapeutics

Agile ended 1Q 2020 with nearly $94M in cash as it prepares to commercialize Twirla contraceptive

CEO Al Altomari called quarter that ended March 31 'transformational' as the FDA approved its flagship product

Agile Therapeutics - Agile Therapeutics Inc (NASDAQ:AGRX) ends first quarter of 2020 with nearly $94 million in cash and cash equivalents as it prepares to commercialize its Twirla patch contraceptive
The New Jersey company expects to bring Twirla to market in the fourth quarter of 2020

Agile Therapeutics Inc (NASDAQ:AGRX), which is preparing to commercialize its Twirla patch contraceptive, closed out its first quarter of 2020 with nearly $94 million in cash and cash equivalents. 

In a statement Tuesday, CEO Al Altomari called the quarter that ended March 31 “transformational” for the company. 

In February Agile achieved a major milestone -- it won US Food and Drug Administration approval of Twirla, a low-dose prescription contraceptive delivered through the skin via the company’s proprietary patch technology.

READ: Agile announces pricing of underwritten public offering expected to raise about $45M

Altomari said New Jersey-based Agile is moving forward -- despite the coronavirus (COVID19) shutdown and health crisis -- with its precommercial activities to bring Twirla to market in the fourth quarter of 2020.

“With respect to our manufacturing process, we have completed production of the pre-validation batch and subject to final quality control testing that we expect to be completed soon, we will transition into the final validation phase,” Altomari said. “We plan to initiate the manufacture of our validation batches at the same time that we expect to build our sales force and commercial infrastructure to facilitate the product launch.”

Altomari added: “By raising more than $68 million in debt and equity financing in recent months, we expect to have the financial runway needed to achieve our next milestone, which is the initial shipment of Twirla, so that we can begin taking a share of the $4.1 billion estimated potential addressable market. It was a transformational quarter for Agile with FDA approval of Twirla, a truly game-changing moment that now enables us to focus on commercialization.”

In the second quarter of 2020, the company said it plans to begin hiring and training an initial sales team, which it estimates to be in the range of 70 to 100 people. It intends to begin to ship product to wholesalers in the fourth quarter of 2020.

Outlook for 2020

Moving forward, the company said it plans to monitor spending closely and expects operating expenses for the full year 2020 to be in the range of $52 million to $56 million, with general and administrative expenses accounting for about 70% of the spending as it builds out its commercial infrastructure.  

Net revenue in the fourth quarter of 2020, reflecting the initial launch of Twirla, is expected to be in the range of $4 million to $6 million, Agile said.  

Based on the company’s current business plan and ability to get Twirla launched, Agile said it believes that its cash and cash equivalents as of March 31 will be sufficient to meet its projected operating requirements through the end of 2021.  

If the COVID-19 outbreak or other factors impact the company’s business plan or its ability to generate revenue from the launch of Twirla, Agile said it believes it has the ability to revise its commercial plans, including curtailing sales and marketing spending, to allow it to continue to fund its operations. 

Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham

Quick facts: Agile Therapeutics

Price: 2.75 USD

Market: NASDAQ
Market Cap: $240.9 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Agile Therapeutics named herein, including the promotion by the Company of Agile Therapeutics in any Content on the Site, the Company receives...


Agile Therapeutics commercially launches its women's contraceptive patch...

Agile Therapeutics, Inc. (NASDAQ:AGRX) CEO Al Altomari tells Proactive the Princeton, New Jersey-based women’s healthcare company has commercially launched its low-dose, non-daily contraceptive patch for women named Twirla. Altomari says the group has built a system that can adapt to business...

on 12/09/2020

3 min read